Where the API is routed into closed-loop poultry drinking-water medication systems, the limiting process variable is not solubility but oxidative degradation of chlorogenic acid and related caffeoyl esters during stock-solution hold time. A stainless steel or high-density polyethylene header tank is charged with non-chlorinated water, the soluble powder is added under low-shear agitation, and the concentrate is injected by a piston-diaphragm proportioner calibrated against the drinker-line flow rate. The final in-water dose must follow the registered label for the target species and production category; no universal inclusion rate can be assigned because authorized formulations differ by jurisdiction and by extract marker content. Water with free chlorine above 0.5 mg/L is dechlorinated by granular activated carbon or sodium thiosulfate before reconstitution, since the ortho-dihydroxyphenyl residues in chlorogenic acid oxidize to quinoid products that form haze and lose activity. Medicated drinking water is prepared fresh within a 24 h use window, with line flushes before and after the treatment period. In food-producing species such as broilers and turkeys, use is restricted to registered products, with withdrawal periods under Regulation (EU) 2019/6 and national residue control programmes applied before slaughter; egg-producing flocks require explicit label authorization. The terminal product is the drinker-delivered solution itself, not a dried dosage form, and the batch record should capture reconstitution volume, source-water pH, chlorine residual, proportioner stroke rate, and final visual clarity.

When Does Premix Segregation Become Irreversible in Swine Feed Manufacturing?

The dry powder is incorporated into swine feed through a staged geometric dilution sequence, because direct addition of a low-density herbal extract to a maize-soybean meal mixer produces migration during discharge and auger transfer. The first stage blends 1 part API with 9 parts carrier in a twin-shell V-blender or rotary batch mixer at 15–25 rpm for a product-specific time determined by a mixing uniformity study. The second stage disperses this pre-blend into a trace-mineral premix at 1:10, and the third stage adds the diluted premix into the finished feed at the approved kilogram-per-tonne inclusion. Mixing acceptance is based on marker analysis, typically baicalin by HPLC-UV at 277 nm or chlorogenic acid at 327 nm, with a coefficient of variation below 5% across sampled points. The API is hygroscopic; storage of opened bags above 65% RH leads to caking, poor screw-conveyor discharge, and uneven dosing. The finished product is a medicated premix or finished feed under Regulation (EU) 2019/4 where applicable, or an equivalent national medicated feedingstuffs approval. In the United States, manufacture must meet 21 CFR 210/211 if the premix is a finished veterinary pharmaceutical, and feed-use products must follow applicable medicated feed regulations. The terminal product is a homogeneous feed or premix with retained samples tested for marker content, moisture, and dust load.

Tablet Granulation End-Point and Extract Moisture Sorption

Wet granulation is preferred over direct compression because the spray-dried herbal extract has poor flow, high wall friction, and a tendency to stick at compression speeds above modest press outputs. A top-spray fluid-bed granulator is operated with inlet air at 50–60°C, a dew point below 8°C, and a binder solution containing povidone K30 at 2–5 wt% of dry granule mass. Granulation is stopped at a loss-on-drying of 1–3%, because overwetting extracts cause case hardening and undermilling produces fines that laminate during tablet ejection. The press is run with a main compression force between 10 kN and 20 kN on a rotary tablet press, with precompression used where capping appears. Hardness is not a single value; it is set against disintegration in simulated gastric or saliva fluid, and the API extract can prolong disintegration if granules are excessively dense. Compliance follows cGMP under 21 CFR 210/211 or national veterinary pharmaceutical rules, with release tests including assay of chlorogenic acid at 327 nm, uniformity of dosage units, dissolution where the pharmacopoeial method exists, and a limit on degradation products. The terminal product is a film-coated tablet for companion animals, packaged in aluminium/PVC or aluminium/aluminium blisters with desiccant because the extract is moisture- and light-sensitive. Stability protocols follow VICH GL3 with conditions such as 25°C/60% RH and 40°C/75% RH applied according to the intended marketing region.

When Sterile Filtration Is Required Before Injection Fill

Conversion of the soluble powder into a parenteral solution is the most restrictive downstream route. The API as supplied for oral powders, granules, and premixes is not automatically sterile, apyrogenic, or particulate-controlled; it cannot be dissolved and injected without quarantine release, bioburden testing, and bacterial endotoxin evaluation. Water for Injection is degassed, the powder is dissolved under low-shear vacuum, and the pH is adjusted into the product-specific range that maintains baicalin in solution; pH drift during cooling and storage is a known precipitation risk because the relevant phenolic acid fraction is pH-sensitive. The solution is clarified through 0.45 µm and 0.22 µm PVDF or PES membranes before aseptic filling. Aseptic filling is conducted under ISO 14644-1 Class 5 conditions, with sterilized Type I borosilicate glass vials, chlorobutyl stoppers, and nitrogen overlay where oxidative stability data require. Terminal sterilization at 121°C for 15 min is not universally suitable; published data for this specific configuration are limited, and marker loss during autoclaving must be confirmed by product-specific recovery studies. The final injection is tested for sterility, bacterial endotoxins, particulate matter, pH, and marker content. Use is restricted to the approved species and route; intravenous administration is not extrapolated from oral or drinking-water experience, and rapid intravenous push carries a risk of histamine-release reactions associated with polyphenol-rich extracts. Withdrawal periods apply to food-producing animals.

For neonatal ruminant oral drenches, the powder is reconstituted in deionized water at 20–30°C and delivered by a calibrated drenching gun in dose volumes of 5–20 mL per animal depending on body weight and label dose. Reconstituted drench is not a true solution if the powder contains plant-derived polysaccharides or insoluble excipients; a low-shear mixer is used until visual dispersion is uniform, and the product is passed through a 500 µm screen to protect nozzle flow. The water used should be non-chlorinated and should not contain high hardness salts that precipitate anionic extract fractions. The finished oral liquid is used immediately or refrigerated at 2–8°C for a short designated hold time; the soluble powder does not by itself confer long-term microbiological or preservative stability. Compliance for oral liquids in food-producing species includes withdrawal and waste-milk restrictions under Regulation (EU) 2019/6 or national rules, and the product is not sterile. The terminal product is a drench or oral solution for calves, lambs, or other approved neonatal ruminants, labelled with species, dose volume, treatment period, and withdrawal interval.

Dry-Blending Granules for Milk Replacer Without Triggering Demixing

Dry blending the API into milk replacer or starter feed requires a granular intermediate rather than the raw spray-dried powder. The raw powder has a high fine fraction and poor flow; if mixed directly, fines migrate downward in totes and auger systems and produce marker variation across feeding periods. A fluid-bed spray granulation step converts the extract into compact granules with a target sieve cut between 150 µm and 500 µm using ISO 565 test sieves, selected to overlap with the particle-size distribution of the milk replacer base. The inclusion follows a staged dilution: a 1:10 pre-blend with a mineral carrier, then a 1:100 dilution into the finished batch. Moisture is held below 5%, and the granulated product is packed in polyethylene-lined paper sacks or bulk bags with desiccant where distribution crosses high-humidity zones. Mixing uniformity is assessed by sampling multiple points and determining the coefficient of variation for baicalin at 277 nm; values below 5% are the usual acceptance limit. Compliance is framed by the same medicated feedingstuffs rules as premixes, including Regulation (EU) 2019/4 for homogeneous incorporation and carry-over prevention in the EU. The terminal product is a dust-free granular top-dress or milk-replacer additive with no visible free fines, a tapped density matched to the carrier, and retained samples for marker and moisture release.

Encapsulation of the extract into two-piece hard gelatin capsules is limited to smaller companion animal dose forms where the full dose can be delivered in one or two capsules; large animals are generally dosed by drench, tablet, or feed instead. The powder is blended with 0.5–1.0 wt% colloidal silicon dioxide as a glidant and 0.25–1.0 wt% magnesium stearate as a lubricant in a low-shear tumble blender. The fill moisture is held below 10% to prevent capsule shell embrittlement or softening, and the filling machine is run with reduced dosing-disc speed because the extract generates dust and static charge that increase weight variability. The final capsule contains the herbal extract blend and is packaged in aluminium/PVC or aluminium/aluminium blisters with a desiccant sachet; light and oxygen barrier are required because phenolic marker compounds are photolabile. Compliance for companion animal capsules requires cGMP under 21 CFR 210/211 or national equivalents, with release testing for fill weight variation, marker content, moisture, and microbial load. The terminal product is a hard capsule, not a food supplement, when sold as a registered veterinary medicinal product; in jurisdictions where the product is a herbal supplement, labelling restrictions differ and therapeutic claims are controlled separately.